Ultrasound and Functional Thyroid Evaluation

Sponsor
Princess Anna Mazowiecka Hospital, Warsaw, Poland (Other)
Overall Status
Recruiting
CT.gov ID
NCT04208503
Collaborator
(none)
200
2
24.4
100
4.1

Study Details

Study Description

Brief Summary

Thyroid disorders are most commonly concomitant with prematurity and still remains a controversial topic. The incidence of a temporary form of hypothyroidism among preterm neonates is higher than in the general population. Transient prematurity hypothyroxinemia is defined as a temporary reduction in FT4 values without increase in TSH values. Currently, there is no consensus about normal thyrotropine (TSH) and free thyroxine (FT4) values in preterm infants.

The aim of this study is to determine the volume of the thyroid gland in preterm infants born between 24 and 32 weeks of gestation inborn or admitted to the unit within 14 days from birth and compare it with the results of TSH and FT4 blood concentration. Besides, the objective of the study is to determine values of thyroid hormones in premature infants born before 33 wk gestation to help neonatologist to interpreter the thyroid hormone results

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: thyroid ultrasound

Detailed Description

Thyroid disorders are most commonly concomitant with prematurity and still remains a controversial topic. Preterm infants are susceptible to thyroid disorders due to many reasons including immaturity of hypothalamopituitary-thyroid axis, non-thyroidal illness, impaired synthesis and metabolism of thyroid hormones, medication administration like dopamine, steroids, caffeine.The incidence of a temporary form of hypothyroidism among preterm neonates is higher than in the general population. Transient prematurity hypothyroxinemia is defined as a temporary reduction in FT4 values without increase in TSH values. It is a diagnostic challenge in order to differentiate it from thyroid disfunction in the critically ill patient. Currently, there is no consensus about normal thyrotropine (TSH) and free thyroxine (FT4) values in preterm infants. Given the delayed appearance of TSH value increase in preterm newborns additional thyroid evaluation methods are sought. We believe the thyroid ultrasound might prove helpful.

The aim of this study is to determine the volume of the thyroid gland in preterm infants born between 24 and 32 weeks of gestation inborn or admitted to the unit within 14 days from birth and compare it with the results of TSH and FT4 blood concentration. We will performed the thyroid ultrasound to estimate the thyroid volume to aid in the comparative evaluation of infants with suspected thyroid disease. The value of sonography thyroid volume will give specialists possibility to identify a gland as normal, small or enlarged. Besides, the objective of the study is to determine value of thyroid hormones in premature infants born before 33 wk gestation to help neonatologist to interpreter the thyroid hormone results

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Ultrasound and Functional Thyroid Evaluation in Preterm Infants Born Between 24 and 32 Weeks of Gestation
Actual Study Start Date :
Dec 19, 2019
Anticipated Primary Completion Date :
Dec 30, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Outcome Measures

Primary Outcome Measures

  1. Determination of FT4 and TSH values in preterm infants born at 24-28 weeks of gestation [14-21 days of life, at 32 and 36 weeks of PCA]

    FT4 and TSH - blood concentration

  2. Determination of FT4 and TSH values in preterm infants born at 29-32 weeks of gestation [at 14-21 day of life, at 32 and 36 weeks of PCA]

    FT4 and TSH - blood concentration

  3. Determination of ultrasound thyroid volume in both groups of preterm infants (i.e., those born at 24-28 weeks of gestation and those born at 29-32 weeks of gestation) [at 32 and 36 weeks of PCA]

    The thyroid volume

  4. Evaluation of correlations between circulating thyroid hormone concentrations and thyroid volume [at 32 and 36 weeks of PCA]

    comparison of values of FT4, TSH and thyroid volume

Secondary Outcome Measures

  1. Comparison of changes in FT4 evaluated at 32 and 36 weeks of PCA in each group of preterm infants [at 14-21 day of life, at 32 and 36 weeks of PCA]

    comparison of results

  2. Comparison of changes in TSH evaluated at 32 and 36 weeks of PCA in each group of preterm infants [14-21 days of life, at 32 and 36 weeks of PCA]

    comparison of results

  3. Analysis of TSH values over time (to determine the optimal time for TSH measurement) [at 14-21 day of life, at 32 and 36 weeks of PCA]

    Intervention time

  4. Evaluation of changes in ultrasound thyroid volume examined at 32 and 36 weeks of PCA in each group of preterm infants [at 32 and 36 weeks of PCA]

    comparison of results

  5. Evaluation of the correlation between thyroid volume and circulating thyroid hormone concentrations with the head circumference and body mass at 32 and 36 weeks of PCA [at 32 and 36 weeks of PCA]

    correlation of results with the body mass and the head circumference

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Week to 12 Weeks
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • preterm infants born between 24 and 32 weeks of gestation (estimated by ultrasound)

  • in born or admitted to the unit within one week from birth

  • randomization within 7 days from birth

  • parental consent

Exclusion Criteria:
  • preterm delivery <23 weeks of gestation or > 32 weeks (estimated by ultrasound)

  • major congenital abnormalities

  • no parental consent

  • medications used after birth: steroids, vasopressors (up to 12 hours after end of treatment)

  • positive thyroid stimulating antibodies (TSAb) in the mother

  • mothers with thyroid disease treated with antythyroid drugs

  • mothers treated with amiodarone

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Neonatology and Neonatal Intensive Care Warsaw Medical University Warsaw Poland 00-315
2 Department of Neonatology and Neonatal Intensive Care Warsaw Medical University Warsaw Poland

Sponsors and Collaborators

  • Princess Anna Mazowiecka Hospital, Warsaw, Poland

Investigators

  • Study Chair: Aleksandra Mikolajczak, MD PhD, Princess Anna Mazowiecka

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Princess Anna Mazowiecka Hospital, Warsaw, Poland
ClinicalTrials.gov Identifier:
NCT04208503
Other Study ID Numbers:
  • 3/2019
First Posted:
Dec 23, 2019
Last Update Posted:
Aug 16, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Princess Anna Mazowiecka Hospital, Warsaw, Poland
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2021